Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: FDA

LifeSignals receives FDA 510 (k) Approval for LifeSignals LX1550 Multiparameter Remote Monitoring Platform


FREMONT, Calif., July 27, 2021 /CNW/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform. This follows recent CE marking and is further validation of LifeSignals' drive to create innovative wireless platforms which can be used by clinicians for the continuous collection of patient physiological data at home and in healthcare settings.

Central to the platform is a single-use wearable multiparameter biosensor that records Electrocardiography (2-channel ECG), Heart Rate, Respiration Rate, Skin Temperature and Body Posture data for up to five days. The encrypted physiological data can then be transmitted with high reliability from the biosensor, via a relay app to a secure cloud-based platform. Clinicians and Care Providers can access the cloud-based remote monitoring dashboard to view patient physiological data and manage alert settings.

The Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location. The relay app and dashboard are developer-friendly with ready-to-deploy software development kit APIs and is suitable for large scale implementation.

"COVID-19 has broken down the barriers to remote patient monitoring globally and I am proud of how the LifeSignals team has responded to develop the Platform in such a short space of time," says Surendar Magar, Founder and CEO. "This FDA 510 (k) approval marks another major milestone in the company's development and mission. It has already been implemented successfully in hospitals for monitoring COVID-19 patients in India and is being rolled out in Europe, UK, Singapore and the Philippines. Our focus now is to rapidly introduce low-cost remote vital sign monitoring to US healthtech companies looking to expand their services and improve patient care."

www.lifesignals.com

Photo - https://mma.prnewswire.com/media/1582121/LifeSignals.jpg

 

SOURCE LifeSignals Inc


These press releases may also interest you

at 04:00
OPEN Health has today announced the acquisition of London-based agency ARK. ARK has a unique approach to delivering data-driven, digital-first creative campaigns. Integrating the ARK business with the OPEN Health Group further strengthens our global...

at 04:00
Taiwania Capital, the first venture capital investment firm funded by the Taiwanese government, has demonstrated its investing prowess through the successful public listings of five portfolio companies in the U.S. and Taiwan: EirGenix, Inc. (with a...

at 04:00
The chronic condition IBD is marked by recurring phases of inflammation and remission of the gastrointestinal tract. With adequate treatment, the symptoms of the disease can be effectively managed for many patients to help improve their quality of...

at 03:30
Mind Cure Health Inc. (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licensing agreement with ATMA Journey Centers Inc. ("ATMA"), a pioneer in...

at 03:19
exocad GmbH (exocad), an Align Technology, Inc. company and a leading dental CAD software provider, detailed the company's achievements over the past year and recent productivity-boosting software innovations at its International Dental Show (IDS)...

at 03:05
Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test....



News published on 27 july 2021 at 07:00 and distributed by: